The discovery of miR‐130b/PTEN being a new regulator that controls cisplatin‐resistance in lung cancer offers a fresh molecular insight that might be utilized in new therapy development for cisplatin resistance in lung cancer. This evidence concerns the gene PTEN and lung carcinoma.